The Biotech Brief

6: From Approval to Access

Gilead’s twice-yearly injectable PrEP, Yeztugo was recently approved by the FDA, but the story doesn’t end there. In this episode of The Biotech Brief, we explore how Gilead is leveraging global partnerships, generics, and regulatory streamlining to deliver Yeztugo to low- and middle-income countries without delay. Building on Episode 1, “Changing the Game in HIV Prevention,” this follow-up digs into what equitable access really takes and what drug developers can learn from it.

5: Street Pricing, Corporate Cartels, and the Generic Drug Price War

Southwest Airlines is taking generic drugmakers to court and accusing more than 20 companies of price fixing that inflated costs for millions of Americans, including its own employees. In this episode of The Biotech Brief, we unpack the lawsuit, the history of generic drug cartel behavior, and why drug developers (yes, even biotech innovators) should be paying close attention. This episode explores how drug pricing moves from boardroom strategy to national scandal.

4: Rebranding Vision

Ocular Therapeutix is rebranding and repositioning. This episode of The Biotech Brief breaks down their plans for competing in the Wet AMD space, the company’s brand pivot to be more retina focused, and why this branding shift is more strategic than cosmetic.

3: Disappointing Data. Cosentyx Doesn’t Deliver in Giant Cell Arteritis

Novartis’ blockbuster Cosentyx has hit a wall. In this episode of The Biotech Brief, we unpack the Phase 3 GCAptAIN trial results, where Cosentyx failed to show benefit for patients with giant cell arteritis. We explore what GCA is, why this label expansion mattered, and how the drug—once seen as a contender in this space—fell short. Plus, we look at the commercial implications, the competitive IL-6 landscape, and what this means for the future of Cosentyx and Novartis’ inflammatory disease pipeline.

2: Twice the Targets, A Newly Approved Bispecific Enters the Myeloma Arena

Regeneron has officially entered the multiple myeloma arena with FDA approval of Lynozyfic, a BCMA-targeted bispecific antibody for patients who’ve exhausted standard therapies. In this episode, we break down what Lynozyfic is, how it works, and how it stacks up against competitors.

1: Changing the Game in HIV Prevention

In the first episode of The Biotech Brief, we break down what Yeztugo is, why it matters, how it compares to daily pills, and what this means for the $45 billion HIV prevention market.